Source: Drug Design, Development and Therapy. Unidade: FM
Subjects: LEUCEMIA MILÓIDE (TERAPIA), CROMATOGRAFIA, BIOEQUIVALÊNCIA, REAÇÃO EM CADEIA POR POLIMERASE, ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REZENDE, Vinicius Marcondes et al. Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Design, Development and Therapy, v. 7, p. 699\2013710, 2013Tradução . . Disponível em: https://doi.org/10.2147/DDDT.S42902. Acesso em: 16 maio 2024.APA
Rezende, V. M., Rivellis, A., Novaes, M. M. Y., Chamone, D. de A. F., & Bendit, I. (2013). Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Design, Development and Therapy, 7, 699\2013710. doi:10.2147/DDDT.S42902NLM
Rezende VM, Rivellis A, Novaes MMY, Chamone D de AF, Bendit I. Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays [Internet]. Drug Design, Development and Therapy. 2013 ; 7 699\2013710.[citado 2024 maio 16 ] Available from: https://doi.org/10.2147/DDDT.S42902Vancouver
Rezende VM, Rivellis A, Novaes MMY, Chamone D de AF, Bendit I. Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays [Internet]. Drug Design, Development and Therapy. 2013 ; 7 699\2013710.[citado 2024 maio 16 ] Available from: https://doi.org/10.2147/DDDT.S42902
